Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) EBIT (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed EBIT for 11 consecutive years, with -$2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT rose 10.97% to -$2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$14.9 million, a 1133.47% decrease, with the full-year FY2024 number at -$11.1 million, down 277.15% from a year prior.
  • EBIT was -$2.1 million for Q3 2025 at Marker Therapeutics, up from -$4.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $8.7 million in Q4 2023 to a low of -$10.9 million in Q2 2021.
  • A 5-year average of -$4.5 million and a median of -$4.1 million in 2023 define the central range for EBIT.
  • Biggest YoY gain for EBIT was 386.16% in 2023; the steepest drop was 265.48% in 2023.
  • Marker Therapeutics' EBIT stood at -$9.8 million in 2021, then soared by 68.88% to -$3.0 million in 2022, then surged by 386.16% to $8.7 million in 2023, then tumbled by 144.41% to -$3.9 million in 2024, then surged by 44.66% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's EBIT are -$2.1 million (Q3 2025), -$4.3 million (Q2 2025), and -$4.6 million (Q1 2025).